HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Kura Oncology (NASDAQ:KURA) with a maintained price target of $32.

May 14, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kura Oncology receives a reiterated Buy rating and a $32 price target from HC Wainwright & Co., indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and a specific price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside based on the firm's analysis. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100